Summary:
Help ENLIGHTEN MASH/NASH treatment options. Together, let’s find a treatment for MASH/NASH to reduce the worsening of cirrhosis and development of complications of cirrhosis. Consider joining the ENLIGHTEN Cirrhosis study, which is researching the investigational drug, pegozafermin.
Summary: The ENLIGHTEN Cirrhosis study is a phase 3 clinical trial for people with fatty liver disease, otherwise known as MASH/NASH, studying the effectiveness and safety of the study medication, pegozafermin. This study is for people aged 18-75 who have been confirmed to have MASH/NASH with cirrhosis. Together, we aim to provide a potential treatment and reduce the risk of cirrhosis worsening.
Criteria:
- Age 18-75
- Willing to undergo a biopsy of the liver to confirm MASH/NASH cirrhosis at screening and again after 2 years of treatment
- Diagnosed with Cirrhosis due to MASH/NASH